Coronary microvascular dysfunction and cardiovascular disease: Pathogenesis, associations and treatment strategies
Open Access
- 13 June 2023
- journal article
- research article
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 164, 115011
Abstract
No abstract availableKeywords
Funding Information
- National Natural Science Foundation of China (82174326)
- State Administration of Traditional Chinese Medicine of the People's Republic of China (ZYYCXTD-C-202203)
- Shanghai University of Traditional Chinese Medicine (YJSKC-20211012)
- Tianjin Research Innovation Project for Postgraduate Students (2021YJSB294)
This publication has 152 references indexed in Scilit:
- In women with symptoms of cardiac ischemia, nonobstructive coronary arteries, and microvascular dysfunction, angiotensin-converting enzyme inhibition is associated with improved microvascular function: A double-blind randomized study from the National Heart, Lung and Blood Institute Women's Ischemia Syndrome Evaluation (WISE)American Heart Journal, 2011
- Effect of Phosphodiesterase Type 5 Inhibition on Microvascular Coronary Dysfunction in Women: A Women's Ischemia Syndrome Evaluation (WISE) Ancillary StudyClinical Cardiology, 2011
- Ranolazine Improves Angina in Women With Evidence of Myocardial Ischemia But No Obstructive Coronary Artery DiseaseJACC: Cardiovascular Imaging, 2011
- Effects of smoking on coronary microcirculatory function: A twin studyAtherosclerosis, 2011
- An Intravascular Ultrasound Analysis in Women Experiencing Chest Pain in the Absence of Obstructive Coronary Artery Disease: A Substudy from the National Heart, Lung and Blood Institute–Sponsored Women's Ischemia Syndrome Evaluation (WISE)Journal of Interventional Cardiology, 2010
- Global Cardiovascular Reserve Dysfunction in Heart Failure With Preserved Ejection FractionJACC, 2010
- Myocardial microvascular function during acute coronary artery stenosis: effect of hypertension and hypercholesterolaemiaCardiovascular Research, 2009
- The effects of the angiotensin II receptor (type I) antagonist irbesartan in patients with cardiac syndrome X: Table 1Heart, 2007
- Clinical and functional determinants of coronary flow reserve in non-ischemic dilated cardiomyopathyInternational Journal of Cardiology, 2005
- Relationships between coronary flow vasodilator capacity and small artery remodelling in hypertensive patients.Journal Of Hypertension, 2003